Aligos Therapeutics, Inc.ALGSNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank14
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P14
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2025-9.25%
2024-25.43%
202315.93%
2022-7.42%
202195.14%
202046.12%
2019212.17%
20180.00%